PEN

ACCE-researched
Penumbra Inc. Common Stock
Healthcare · Medical Devices · NYSE · United States
$317.60-0.40%
Market cap $12.5BNext earnings 2026-11-04Updated Sep 19, 2026
FAIR VALUE · CONSENSUS
$317.60+0.0%
confidence-weighted across 4 of 6 models
Now $317.60
$317.60
$60.61$208.08
AvoidBronze40
Price vs fair value
152.8% above
-60.4% to fair value
ACCE score
46
out of 100
Analysts
78% buy
18 covering
P/E
78.0x
forward 55.2x
1-year return
+23.2%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOR

Overview

Reports in 44 days, last quarter missed by 0.2%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+25.2% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Bullish78% buy · 18 covering analysts
● Strong buy 12● Buy 2● Hold 4● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 0.0x78.0xhigh 78.0x
ROEbetter than 33% of peers
low -9%11%high 26%
Div yieldbetter than 67% of peers
low 0.0%0.0%high 3.8%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
SNNSmith & Nephew SNATS Inc. Common Stock$11.5B18.711.8%0.592.9%-Compare
SN.LSmith & Nephew plc$11.5B18.711.8%0.593.8%-Compare
BIOBio-Rad Laboratories Inc. Class A Common Stock$10.1B45.83.1%0.160.0%-Compare
TXG10x Genomics Inc. Class A Common Stock$10.0B--9.4%0.010.0%-Compare
GMEDGlobus Medical Inc. Class A Common Stock$9.9B18.911.8%0.000.0%-Compare
PODDInsulet Corporation Common Stock$9.8B26.426.0%0.630.0%-Compare

Sector report card

Where PEN ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 44 days, last quarter missed by 0.2%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
-0.0%
1 month
-2.8%
3 months
+0.1%
6 months
-5.4%
YTD
+2.2%
1 year
+23.2%

SEC filings

36 filings
September 2026
Sep 17
Form 4Insider transactionPeriod 2026-09-15
August 2026
Aug 19
Form 4Insider transactionPeriod 2026-08-17
July 2026
Jul 30
10-QQuarterly reportPeriod 2026-06-30
33 more filings + AI summaries on Investor+.INVESTOR